|
|
|
|
||
UBS raised PT to $34 in Dec & had a PGR call Jan 4thJust a wag but if UBS expected CNCE to lose the upcoming Jan PGR you'd think they would have reduced their PT for CNCE which was just raised in Dec. When raising their PT to $34 they specifically cited as the reason for the upgrade is the substantial opportunity CNCE's deuterated ruxo provides in alopecia areata. I didn't get to hear the Jan 4th call but I'm assuming UBS believes CNCE will win the PGR decision which should arrive any day now. ------------------------------------------------------------------------ CNCE 01/04/18 UBS biotech analysts hold an analyst/industry conference call Biotech Analysts Hung and Gould discuss Concert's Post Grant Review Petition against Incyte's U.S. Patent #9,662,335, which the Patent Trial and Appeal Board is expected to make a decision on in January 2018, on an Analyst/Industry conference call to be held on January 4 at 1 pm. CNCE 12/19/17 Concert Pharmaceuticals analyst commentary at UBS UBS analyst Jeffrey Hung raised his price target on Concert Pharmaceuticals to $34 from $22 to reflect higher than expected demand for novel alopecia treatments. He continues to see a substantial opportunity for its alopecia treatment and increased his launch assumptions. The analyst also pointed to the company's clinical candidates that demonstrate the strategic value of the platform and pipeline optionality. Hung reiterated his Buy rating on Concert Pharmaceuticals shares. Read more at: https://thefly.com/landingPageNews.php?id=2657089 |
return to message board, top of board |